Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 5/20 | 0.50 |
| ▸ | F2 | P00734 | 7/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | MASP2 | O00187 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11247986 | 0.88 | F2 (0.51) | GRIK1F2HRH3MASP2 | |
| SCHEMBL11247984 | 0.88 | F2 (0.51) | GRIK1F2HRH3MASP2 | |
| SCHEMBL23118028 | 0.84 | GRIK1 (0.49) | GRIK1F2HRH3ARG1MASP2 | |
| SCHEMBL20746440 | 0.83 | GRIK1 (0.53) | GRIK1F2HRH3ARG1 | |
| SCHEMBL29350039 | 0.83 | GRIK1 (0.53) | GRIK1F2HRH3ARG1 | |
| Hydrochloric Acid SCHEMBL30405343 | 0.82 | GRIK1 (0.54) | GRIK1F2HRH3ARG1 | |
| SCHEMBL3182082 | 0.81 | EED (0.53) | GRIK1CYP1A2 | |
| SCHEMBL1706921 | 0.81 | HRH3 (0.54) | GRIK1F2HRH3ARG1MASP2 | |
| SCHEMBL22536533 | 0.81 | HRH3 (0.54) | GRIK1F2HRH3ARG1MASP2 | |
| SCHEMBL19292680 | 0.81 | HRH3 (0.54) | GRIK1F2HRH3ARG1MASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113967258-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-25 | — | — | CN | disclosed |
| CN-113956325-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-21 | — | — | CN | disclosed |